Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy

Josephine M. Forbes, Suzanne R. Thorpe, Vicki Thallas-Bonke, Josefa Pete, Merlin C. Thomas, Elizabeth R. Deemer, Sahar Bassal, Assam El-Osta, David M. Long, Sianna Panagiotopoulos, George Jerums, Tanya M. Osicka, Mark E. Cooper

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Recent studies have identified that first-line renoprotective agents that interrupt the renin-angiotensin system not only reduce BP but also can attenuate advanced glycation end product (AGE) accumulation. This study used in vitro, preclinical, and human approaches to explore the potential effects of these agents on the modulation of the receptor for AGE (RAGE). Bovine aortic endothelial cells that were exposed to the angiotensin-converting enzyme inhibitor (ACEi) ramiprilat in the presence of high glucose demonstrated a significant increase in soluble RAGE (sRAGE) secreted into the medium. In streptozotocin-induced diabetic rats, ramipril treatment (ACEi) at 3 mg/L for 24 wk reduced the accumulation of skin collagen-linked carboxymethyllysine and pentosidine, as well as circulating and renal AGE. Renal gene upregulation of total RAGE (all three splice variants) was observed in ACEi-treated animals. There was a specific increase in the gene expression of the splice variant C-truncated RAGE (sRAGE). There were also increases in sRAGE protein identified within renal cells with ACEi treatment, which showed AGE-binding ability. This was associated with decreases in renal full-length RAGE protein from ACEi-treated rats. Decreases in plasma soluble RAGE that were significantly increased by ACEi treatment were also identified in diabetic rats. Similarly, there was a significant increase in plasma sRAGE in patients who had type 1 diabetes and were treated with the ACEi perindopril. Complexes between sRAGE and carboxymethyllysine were identified in human and rodent diabetic plasma. It is postulated that ACE inhibition reduces the accumulation of AGE in diabetes partly by increasing the production and secretion of sRAGE into plasma.

Original languageEnglish
Pages (from-to)2363-2372
Number of pages10
JournalJournal of the American Society of Nephrology
Volume16
Issue number8
DOIs
Publication statusPublished - 12 Dec 2005
Externally publishedYes

Cite this

Forbes, Josephine M. ; Thorpe, Suzanne R. ; Thallas-Bonke, Vicki ; Pete, Josefa ; Thomas, Merlin C. ; Deemer, Elizabeth R. ; Bassal, Sahar ; El-Osta, Assam ; Long, David M. ; Panagiotopoulos, Sianna ; Jerums, George ; Osicka, Tanya M. ; Cooper, Mark E. / Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. In: Journal of the American Society of Nephrology. 2005 ; Vol. 16, No. 8. pp. 2363-2372.
@article{a27fe541ec4445c4b9cfb4545f607545,
title = "Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy",
abstract = "Recent studies have identified that first-line renoprotective agents that interrupt the renin-angiotensin system not only reduce BP but also can attenuate advanced glycation end product (AGE) accumulation. This study used in vitro, preclinical, and human approaches to explore the potential effects of these agents on the modulation of the receptor for AGE (RAGE). Bovine aortic endothelial cells that were exposed to the angiotensin-converting enzyme inhibitor (ACEi) ramiprilat in the presence of high glucose demonstrated a significant increase in soluble RAGE (sRAGE) secreted into the medium. In streptozotocin-induced diabetic rats, ramipril treatment (ACEi) at 3 mg/L for 24 wk reduced the accumulation of skin collagen-linked carboxymethyllysine and pentosidine, as well as circulating and renal AGE. Renal gene upregulation of total RAGE (all three splice variants) was observed in ACEi-treated animals. There was a specific increase in the gene expression of the splice variant C-truncated RAGE (sRAGE). There were also increases in sRAGE protein identified within renal cells with ACEi treatment, which showed AGE-binding ability. This was associated with decreases in renal full-length RAGE protein from ACEi-treated rats. Decreases in plasma soluble RAGE that were significantly increased by ACEi treatment were also identified in diabetic rats. Similarly, there was a significant increase in plasma sRAGE in patients who had type 1 diabetes and were treated with the ACEi perindopril. Complexes between sRAGE and carboxymethyllysine were identified in human and rodent diabetic plasma. It is postulated that ACE inhibition reduces the accumulation of AGE in diabetes partly by increasing the production and secretion of sRAGE into plasma.",
author = "Forbes, {Josephine M.} and Thorpe, {Suzanne R.} and Vicki Thallas-Bonke and Josefa Pete and Thomas, {Merlin C.} and Deemer, {Elizabeth R.} and Sahar Bassal and Assam El-Osta and Long, {David M.} and Sianna Panagiotopoulos and George Jerums and Osicka, {Tanya M.} and Cooper, {Mark E.}",
year = "2005",
month = "12",
day = "12",
doi = "10.1681/ASN.2005010062",
language = "English",
volume = "16",
pages = "2363--2372",
journal = "Journal of the American Society of Nephrology",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "8",

}

Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. / Forbes, Josephine M.; Thorpe, Suzanne R.; Thallas-Bonke, Vicki; Pete, Josefa; Thomas, Merlin C.; Deemer, Elizabeth R.; Bassal, Sahar; El-Osta, Assam; Long, David M.; Panagiotopoulos, Sianna; Jerums, George; Osicka, Tanya M.; Cooper, Mark E.

In: Journal of the American Society of Nephrology, Vol. 16, No. 8, 12.12.2005, p. 2363-2372.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy

AU - Forbes, Josephine M.

AU - Thorpe, Suzanne R.

AU - Thallas-Bonke, Vicki

AU - Pete, Josefa

AU - Thomas, Merlin C.

AU - Deemer, Elizabeth R.

AU - Bassal, Sahar

AU - El-Osta, Assam

AU - Long, David M.

AU - Panagiotopoulos, Sianna

AU - Jerums, George

AU - Osicka, Tanya M.

AU - Cooper, Mark E.

PY - 2005/12/12

Y1 - 2005/12/12

N2 - Recent studies have identified that first-line renoprotective agents that interrupt the renin-angiotensin system not only reduce BP but also can attenuate advanced glycation end product (AGE) accumulation. This study used in vitro, preclinical, and human approaches to explore the potential effects of these agents on the modulation of the receptor for AGE (RAGE). Bovine aortic endothelial cells that were exposed to the angiotensin-converting enzyme inhibitor (ACEi) ramiprilat in the presence of high glucose demonstrated a significant increase in soluble RAGE (sRAGE) secreted into the medium. In streptozotocin-induced diabetic rats, ramipril treatment (ACEi) at 3 mg/L for 24 wk reduced the accumulation of skin collagen-linked carboxymethyllysine and pentosidine, as well as circulating and renal AGE. Renal gene upregulation of total RAGE (all three splice variants) was observed in ACEi-treated animals. There was a specific increase in the gene expression of the splice variant C-truncated RAGE (sRAGE). There were also increases in sRAGE protein identified within renal cells with ACEi treatment, which showed AGE-binding ability. This was associated with decreases in renal full-length RAGE protein from ACEi-treated rats. Decreases in plasma soluble RAGE that were significantly increased by ACEi treatment were also identified in diabetic rats. Similarly, there was a significant increase in plasma sRAGE in patients who had type 1 diabetes and were treated with the ACEi perindopril. Complexes between sRAGE and carboxymethyllysine were identified in human and rodent diabetic plasma. It is postulated that ACE inhibition reduces the accumulation of AGE in diabetes partly by increasing the production and secretion of sRAGE into plasma.

AB - Recent studies have identified that first-line renoprotective agents that interrupt the renin-angiotensin system not only reduce BP but also can attenuate advanced glycation end product (AGE) accumulation. This study used in vitro, preclinical, and human approaches to explore the potential effects of these agents on the modulation of the receptor for AGE (RAGE). Bovine aortic endothelial cells that were exposed to the angiotensin-converting enzyme inhibitor (ACEi) ramiprilat in the presence of high glucose demonstrated a significant increase in soluble RAGE (sRAGE) secreted into the medium. In streptozotocin-induced diabetic rats, ramipril treatment (ACEi) at 3 mg/L for 24 wk reduced the accumulation of skin collagen-linked carboxymethyllysine and pentosidine, as well as circulating and renal AGE. Renal gene upregulation of total RAGE (all three splice variants) was observed in ACEi-treated animals. There was a specific increase in the gene expression of the splice variant C-truncated RAGE (sRAGE). There were also increases in sRAGE protein identified within renal cells with ACEi treatment, which showed AGE-binding ability. This was associated with decreases in renal full-length RAGE protein from ACEi-treated rats. Decreases in plasma soluble RAGE that were significantly increased by ACEi treatment were also identified in diabetic rats. Similarly, there was a significant increase in plasma sRAGE in patients who had type 1 diabetes and were treated with the ACEi perindopril. Complexes between sRAGE and carboxymethyllysine were identified in human and rodent diabetic plasma. It is postulated that ACE inhibition reduces the accumulation of AGE in diabetes partly by increasing the production and secretion of sRAGE into plasma.

UR - http://www.scopus.com/inward/record.url?scp=28444472740&partnerID=8YFLogxK

U2 - 10.1681/ASN.2005010062

DO - 10.1681/ASN.2005010062

M3 - Article

VL - 16

SP - 2363

EP - 2372

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

SN - 1046-6673

IS - 8

ER -